Australian biopharmaceutical company Dimerix Limited (ASX: DXB) has entered into a collaboration with University of Michigan’s Nephrotic Syndrome Study Network of Rare Kidney Diseases (NEPTUNE) to assist with biomarker profiling and prospectively identifying patients with FSGS most likely to benefit, for the ACTION3 trial via their proprietary NEPTUNE MATCH network.
Based at the University of Michigan in the United States, under the leadership of Dr Matthias Kretzler, NEPTUNE is a leading network for precision medicine in glomerular diseases. NEPTUNE has enrolled more than 1100 participants, from 32 participating sites over the last 16 years.
The overarching goal of NEPTUNE is to collate comprehensive, long-term clinical and molecular data into a resource for better understanding nephrotic syndrome complexities, including FSGS. The NEPTUNE Match precision medicine platform aims to connect patients to the best matching clinical trials based on their disease biomarker profile.
With Dimerix joining the NEPTUNE Match precision trial network, NEPTUNE will help identify patients with FSGS across the United States who meet the inclusion/exclusion criteria, may benefit from a treatment with a mechanism of action such as DMX-200 and refer those patients to the closest ACTION3 clinical trial site, should they wish to participate. Dimerix will also now have the opportunity to collaborate with NEPTUNE to jointly address key research questions using the comprehensive NEPTUNE knowledge network of patients with FSGS.
“This is an extremely important collaboration for the ACTION3 trial as NEPTUNE is the recognised global leader in rare kidney disease research,” Dr David Fuller, Chief Medical Officer of Dimerix, said.
“The Neptune Match programme has a track record of successfully assisting recruitment into trials and should boost our recruitment rate for the ACTION3 trial in the USA while the biomarker work will provide further invaluable insights into the mechanism of action and response to DMX-200 in patients with FSGS.”
